ClinicalTrials.gg
RecruitingNCT07539441Updated Nov 13, 2026

A Study of Mirdametinib in People With Central Nervous System Tumors

A Phase 1/2 interventional study of Mirdametinib in Central Nervous System Tumors and Glioma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 13, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Central Nervous System Neoplasms by Memorial Sloan Kettering Cancer Center — 1 open to participants now, 2 under way, none of them phase 3. Central Nervous System Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
12th of 20
26 · median 30
Started
2026
the only one that year
Phase 1/2
5 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies in Central Nervous System Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 1/2, and was the 27th registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 65 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

1 of the 27 studies in Central Nervous System Neoplasms by Memorial Sloan Kettering Cancer Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 56 Central Nervous System Neoplasms studies recruiting now, 34 (61%) set no upper age limit and 19 (34%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Central Nervous System Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).

03

Conditions studied

  • Central Nervous System Tumors
  • Glioma

Keywords

  • Central Nervous System Tumors
  • Glioma
  • Neurohistiocytosis
  • Mirdametinib
  • Memorial Sloan Kettering Cancer Center
  • 26-103
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Demographic Characteristics

a. Be > 18 years of age

General Criteria

  1. Have Performance Status (KPS) of ≥ 70% or Performance Status of ≤ 2
  2. Is able to understand and provide written for the trial prior to any study-specific procedures and is willing to comply with scheduled visits, treatment plans, procedures and laboratory tests. A legally authorized representative may consent on behalf of a subject who is otherwise unable to provide informed consent, if acceptable to and approved by the institutional review board.

Medical and Therapeutic Criteria

  1. Have adequate bone marrow function, as determined by:

    • (ANC) >1,500/mm3
    • count >100,000 mm³
    • >9.0 mg/dL
  2. Have adequate hepatic function, as determined by:

    • Total ≤1.5 x if baseline was normal or ≤1.5 x baseline if baseline was abnormal. Patients with previously documented Gilbert's Syndrome may have total bilirubin ≤3 x ULN.
    • and ALT ≤3.0 x ULN if baseline was normal or ≤3.0 x baseline if baseline was abnormal
  3. Have adequate renal function, as determined by:

    o (CrCL) of ≥50 mL/min by the Cockcroft-Gault formula

    CrCl (mL/min) = [140 - age (years)] x weight (kg) x 0.85 for female patients 72 creatinine (mg / dL)

  4. Adequate cardiac function defined as follows

    • >50% or higher as assessed by multi-gated acquisition or ultrasound or echocardiography, unless the reduced ejection fraction is deemed by the treating investigator to be the direct result of disease and
    • interval (QTc) \<480 ms according to the Fridericia method (QTcF)
  5. Women of must have a negative serum pregnancy test before the start of therapy.
  6. Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  7. Patients previously treated with radiotherapy must have recovered from acute toxicities associated with such treatment. Toxicities of investigational therapies should have recovered to grade 1 or less before start of the trial medication.

Additional cohort specific inclusion criteria - Neurohistiocytosis Cohort A

Subjects must meet all of the following criteria to be enrolled in the Neurohistiocytosis cohort of this study:

  1. Have documented MAPK pathway mutation, or mutation not identified by tumor sequencing.: Patients with completed but negative tumor sequencing, or patients without sequencing performed but without safe disease sites for , are eligible for this study owing to the high likelihood of MAPK pathway mutation.
  2. Have documentation of disease: Patients must have a confirmed histiocytic neoplasm or a constellation of histologic, radiologic, clinical, and/or molecular findings consistent with histiocytic neoplasm. This qualification is made because it is well known that biopsies of histiocytic neoplasms are variable and do not always demonstrate "typical" morphologic appearance with all of the classically described elements.[54] As a result, histiocytic neoplasms are not exclusively pathologic diagnoses-rather, they are interpretations of histologic findings in a clinical and radiologic context.
  3. Have measurable neurohistiocytic disease: Patients must have measurable radiologic or functional neurologic disease as defined by any of the following below. The presence of systemic disease is allowed however there must be at least one eligible manifestation of neurologic disease as defined below:

    • according to modified PERCIST (mPERCIST) involving neurologic structures, i.e. meninges, brain or spinal cord parenchyma, or ocular structures (see sections below for these criteria) OR
    • Measurable enhancing and/or nonenhancing disease according to based on RANO 2.0 with the addition of minimum size 5mm per RANO-BM OR
    • Any of the below neurologic deficits referable to neurohistiocytosis amenable to longitudinal quantified assessment. The following are the allowable deficits, deemed referable to disease, with their corresponding assessments and minimum required abnormalities:

      • Dysarthria as defined Speech Intelligibility of B or worse as measured by the Frenchay Dysarthria Scale
      • Ataxia as defined by a score of 3 or higher on the Scale for assessment and rating of ataxia (SARA)
      • Diplopia as defined by Prism Diopter of 5 or higher
      • Loss of visual acuity defined as best corrected visual acuity (BCVA) 20/40 (0.3 LogMAR) or worse in either eye
      • Diminished visual field, defined as 20% or higher deficit in Humphrey Visual Field 24-2 pattern deviation.

Additional cohort specific inclusion criteria - Glioma Cohort B

Subjects must meet all of the following criteria to be enrolled in the glioma cohort of this study:

  1. Have: somatic NF1 mutation as per next-generation sequencing (such as MSK Impact) --or- germline NF1 as per NIH clinical criteria
  2. Have a histologically confirmed glioma (per the 2021 WHO Classification of Tumors of the central nervous system)
  3. Have measurable, MRI-evaluable, unequivocal contrast enhancing disease as determined by radiologist on T1 post-contrast weighted images. Per RANO criteria, measurable lesion is defined as at least 1 enhancing lesion measuring > 1 cm x > 1 cm
  4. Have recurrent or progressive disease and received prior treatment with chemotherapy, radiation, or both
  5. Surgical resection is indicated for treatment, but surgery is not urgently indicated (e.g. for whom surgery within the next 4-6 weeks is appropriate)
  6. Have expected survival of > 3 months

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will not be enrolled in the study:

General criteria

  1. Is pregnant or nursing
  2. Is participating in another interventional study at the same time; participation in non-therapeutic registries is allowed

    Medical and Therapeutic criteria

  3. Receipt of tumor directed therapy (chemotherapy, targeted therapy, biologic, ) within 28 days or 5 half-lives (whichever is shorter) before the first dose of mirdametinib. At the investigator's discretion, based on the prior therapy and the patient's clinical status, the window can be reduced to 14 days.
  4. Concomitant use of medications that strongly induce
  5. History of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its ).
  6. Evidence of serious active infections. Patients are allowed to enroll if they have been fever free for at least 48 hours
  7. Uncontrolled or severe intercurrent medical condition
  8. Have significant active cardiac disease within 6 months before the start of treatment, including Class III or IV congestive heart failure, atrial fibrillation, myocardial infarction, unstable angina and/or stroke.
  9. Have significant active ophthalmologic disease within 6 months before the start of treatment, including central retinal vein occlusion
  10. Has a history of or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator
  11. Cohort A only: Patients with documented driver mutations outside of the MAPK pathway are not eligible for this study. These are uncommon and include mutations in ALK, RET, CSF1R, NTRK, and other kinases20 .

On Study Guidelines:

Physicians should consider the following when evaluating if the patient is appropriate for this study:

  • Cohorts A and B: Patients with cytopenias, renal impairment or hepatic impairment deemed the direct result of disease and therefore amenable to improvement with mirdametinib treatment may be enrolled at the discretion of the treating investigator
  • Cohort A: There is no prior therapy requirement given the poor CNS efficacy of standard therapies, morbidity of neurohistiocytosis, and the available data about safety and efficacy in nine patients treated with mirdametinib.
  • The effects of mirdametinib on the developing human fetus are unknown. For this reason, female participants of must agree to use adequate (hormonal or barrier method of birth control; abstinence) during study therapy and for 6 weeks following the completion of study therapy. Male participants with female partners of must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during study therapy and for 3 months following the completion of study therapy. Should a participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Cohort A: Mirdametinib

    11 participants with refractory neurohistiocytosis will be treated with mirdametinib in continuous treatment cycles

    Drug: Mirdametinib

  • Experimental
    Cohort B: Perioperative mirdametinib

    15 participants with recurrent NF1-mutant glioma will be randomized in a 2:1 ratio to receive either perioperative mirdametinib (for 5 days) or no drug before standard of care surgery. All 15 participants will be treated with mirdametinib twice daily after surgery, continuously until clinical or radiographic progression of disease

    Drug: Mirdametinib

  • No intervention
    Cohort B: No perioperative mirdametinib

    15 participants with recurrent NF1-mutant glioma will be randomized in a 2:1 ratio to receive either perioperative mirdametinib (for 5 days) or no drug before standard of care surgery. All 15 participants will be treated with mirdametinib twice daily after surgery, continuously until clinical or radiographic progression of disease

Interventions

  • Mirdametinib is a highly selective and potent, non-ATP-competitive oral inhibitor of MEK1 and MEK2 kinases

06

What researchers measure

Primary outcomes

  1. Best overall neurologic response rate

    To determine the best overall neurologic response rate

    Time frame: 1 year

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Anna Piotrowski, MD · Contact212-610-0483
  • Memorial Sloan Kettering Monmouth (Limited protocol activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Anna Piotrowski, MD · Contact212-610-0483
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Anna Piotrowski, MD · Contact212-610-0483
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Anna Piotrowski, MD · Contact212-610-0483
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Anna Piotrowski, MD · Contact212-610-0483
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Anna Piotrowski, MD · Contact212-610-0483
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Rockville Centre, New York 11570, United States
    Recruiting
    • Anna Piotrowski, MD · Contact212-610-0483
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2029, 42 months after the start.

Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Oct 10, 2029
CompletionEst.
Oct 10, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedLeft ventricular ejection fraction >50% or higher as assessed by multi-gated acquisition or ultrasound or echocardiography, unless the reduced ejection fraction is deemed by the treating investigator to be the direct result of disease and
  • ChangedBefore Measurable disease according to RECIST 1.1 involving neurologic structures ORNow Measurable enhancing and/or nonenhancing disease according to based on RANO 2.0 with the addition of minimum size 5mm per RANO-BM OR
Exclusion criteria
  • EditedReceipt of tumor directed therapy (chemotherapy, targeted therapy, biologic, investigational) within 28 days or 5 half-lives (whichever is shorter) before the first dose of mirdametinib. At the investigator's discretion, based on the prior therapy and the patient's clinical status, the window can be reduced to 14 days.
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedLeft ventricular ejection fraction >50% or higher as assessed by multi-gated acquisition or ultrasound or echocardiography, unless the reduced ejection fraction is deemed by the treating investigator to be the direct result of disease and
    • ChangedBefore Measurable disease according to RECIST 1.1 involving neurologic structures ORNow Measurable enhancing and/or nonenhancing disease according to based on RANO 2.0 with the addition of minimum size 5mm per RANO-BM OR
    Exclusion criteria
    • EditedReceipt of tumor directed therapy (chemotherapy, targeted therapy, biologic, investigational) within 28 days or 5 half-lives (whichever is shorter) before the first dose of mirdametinib. At the investigator's discretion, based on the prior therapy and the patient's clinical status, the window can be reduced to 14 days.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07539441
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 10, 2026
Primary completion
Oct 10, 2029 (estimated)
Completion
Oct 10, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Anna Piotrowski, MD
Contact
piotrowa@mskcc.org
212-610-0483
Eli Diamond, MD
Contact
diamone1@mskcc.org
212-610-0243
Anna Piotrowski, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirdametinib

Start the discussion